Skip to main content
Acta Bio Medica : Atenei Parmensis logoLink to Acta Bio Medica : Atenei Parmensis
. 2020 Nov 9;91(Suppl 13):e2020005. doi: 10.23750/abm.v91i13-S.10596

Genetic analysis of genes associated with epilepsy

Giulia Guerri 1, Marco Castori 2, Leonardo D’Agruma 2, Antonio Petracca 2, Danjela Kurti 3, Matteo Bertelli 1,3,4
PMCID: PMC8023140  PMID: 33170158

Abstract

Background and aim:

Epilepsy is a neurological disorder in which the altered activity of neurons causes convulsions, periods of unusual behavior and, sometimes, loss of consciousness. The aim of this mini-review is to summarize all the syndromes characterized by epilepsy and for which the associated gene is known.

Methods:

We searched those syndromes in PubMed and OMIM database.

Results:

Genetic causes underlie epilepsy in about 40% of individuals. Epilepsies are phenotypically and genetically heterogeneous. Inheritance can be autosomal dominant or recessive or X-linked recessive/dominant.

Conclusion:

Since epilepsy has high genetic heterogeneity, in diagnostics, the parallel sequencing of a panel of genes may speed up the determination of the molecular etiology and/or establish a risk of recurrence in family members for the purpose of planning appropriate preventive and/or therapeutic measures. (www.actabiomedica.it)

Keywords: epilepsy, genetic test, molecular diagnosis


Epilepsy is a neurological disorder in which the altered activity of neurons causes convulsions, periods of unusual behavior and, sometimes, loss of consciousness. The International League against Epilepsy (ILAE) classifies seizures in two main categories: “Idiopathic generalized epileptic seizures” involving both cerebral hemispheres and which can manifest with typical absences, myoclonus and generalized tonic-clonic seizures, alone or in various combinations and severity, and “Focal seizures” that arise in neural networks of a single hemisphere, and are in turn distinguished into simple partial seizures that do not involve an alteration of consciousness, and complex partial seizures that cause a change in behavior or loss of consciousness. Some types of seizures, such as infantile spasms, do not fall into either category (1). Epilepsy may be an isolated neurological symptom or may be associated with other neurological symptoms or diseases (2). Anti-convulsant drugs are the main treatment for epilepsy and often have to be taken throughout life (3). About 1% of the world’s population suffers from epilepsy (4). A diagnosis of epilepsy is based on clinical observation, family history and clinical investigations, such as electroencephalogram, computed tomography and magnetic resonance imaging (5). Syncope, hyperventilation, migraines, narcolepsy, panic attacks and non-epileptic psychogenic seizures can be confused with seizures. In children, some behaviors, such as emotional spasms, bed-wetting, night terrors, tics and myoclonus, can easily be mistaken for epileptic seizures; gastroesophageal reflux can cause arching of the back and sideways head twisting in infants, and this can be confused with tonic-clonic seizures (6). Genetic causes underlie epilepsy in about 40% of individuals (7). Epilepsies are phenotypically and genetically heterogeneous. Inheritance can be autosomal dominant or recessive or X-linked recessive or dominant (Table 1).

Table 1.

Syndromes characterized by epilepsy for which the genetic basis is known.

AD = Autosomal dominant; AR = Autosomal recessive; ADSLD = Adenyl succinase deficiency; AHC = Alternating hemiplegia of childhood; AS = Angelman syndrome; BFIS = Benign familial infantile seizures; BFNS = Benign familial neonatal seizures; CADEDS = Cerebellar atrophy, developmental delay, seizures; CCDS = Cerebral creatine deficiency syndrome; CLN = neuronal ceroid lipofuscinosis; DOORS = Deafness, onychodystrophy, osteodystrophy, mental retardation, seizures syndrome; EA = Episodic ataxia; EEOC = childhood-onset epileptic encephalopathy; EIEE = Early infantile epileptic encephalopathy; EKD = Episodic kinesigenic dyskinesia; ENFL = Nocturnal frontal lobe epilepsy; EPD = Pyridoxine-dependent epilepsy; EPM = Progressive myoclonic epilepsy; EPRPDC = Rolandic epilepsy with paroxysmal exercise-induced dystonia and writer’s cramp; ETL = Familial temporal lobe epilepsy; FCORD = Focal cortical dysplasia; FEB = Familial febrile seizures; FESD = Focal epilepsy with speech disorder with/without mental retardation; FHM = Familial hemiplegic migraine; FIME = Familial infantile myoclonic epilepsy; GEFSP = Generalized epilepsy with febrile seizures plus; GLUT1DS = GLUT1 deficiency syndrome; HPMRS = Hyperphosphatasia with mental retardation syndrome; ICCA = Familial infantile convulsions with paroxysmal choreoathetosis; KDVS = Koolen-De Vries syndrome; KLEFS = Kleefstra syndrome; MAE = Myoclonic-atonic epilepsy; MCAHS = Multiple congenital anomalies-hypotonia-seizures syndrome; MCSZ = Microcephaly, seizures, developmental delay; MEDS = Microcephaly, epilepsy, diabetes syndrome; MICPCH = Mental retardation and microcephaly with pontine and cerebellar hypoplasia; MOWS = Mowat-Wilson syndrome; MRD = Mental retardation; MRX = X-linked mental retardation; MRXSCH = Syndromic X-linked mental retardation, Christianson type; MRXSH = Syndromic X-linked mental retardation, Hedera type; MTDPS = Mitochondrial DNA depletion syndrome; MYOCL = Familial myoclonus; NDHMSD/R = autosomal dominant/recessive neurodevelopmental disorder with or without hyperkinetic movements and seizures; NEDCAS = Neurodevelopmental disorder with cerebellar atrophy with/without seizures; NBIA = Neurodegeneration with brain iron accumulation; PMSE = Polyhydramnios, megalencephaly, symptomatic epilepsy; PNKD = Paroxysmal nonkinesigenic dyskinesia with/without generalized epilepsy; PNPOD = Pyridoxamine 5-prime-phosphate oxidase deficiency; PTHS/L = Pitt-Hopkins syndrome/-like; PVNH = Periventricular nodular heterotopia; RESDX = X-linked Rolandic epilepsy, mental retardation, speech dyspraxia; RMFSL = Lethal neonatal rigidity and multifocal seizure syndrome; RTT = Rett syndrome; SANDO = Sensory ataxic neuropathy, dysarthria, ophthalmoparesis; SESAMES = Seizures, sensorineural deafness, ataxia, mental retardation, electrolyte imbalance; SMAPME = Spinal muscle atrophy with progressive myoclonic epilepsy; THMD = Thiamine metabolism dysfunction syndrome; XLD/R = X-linked, dominant/recessive.

Gene OMIM gene Disease OMIM disease Inheritance Protein function (https://www.genecards.org/)
ATP1A2 182340 AHC1, FHM2 104290, 602481 AD Catalytic subunit of the pump that maintains an essential electrochemical gradient in cells through active transport of Na+ and K+ ions
ATP1A3 182350 AHC2 614820 AD Catalytic subunit of the pump that maintains an essential electrochemical gradient in cells through active transport of Na+ and K+ ions
CACNA1A 601011 EIEE42 617106 AD Mediation of Ca2+ influx in response to depolarization. Regulation of neurotransmission
CHD2 602119 EEOC 615369 AD Chromatin remodeling
CHRNA2 118502 ENFL4 610353 AD Alpha subunit of the nicotinic acetylcholine receptor involved in fast synaptic transmission
CHRNA4 118504 ENFL1 600513 AD Integral membrane receptor subunit of the nicotinic acetylcholine receptor
CHRNB2 118507 ENFL3 605375 AD Beta subunit of the neuronal acetylcholine receptor
CPA6 609562 ETL5, FEB11 614417, 614418 AD, AR Proteolytic inactivation of enkephalins and neurotensin. Conversion of inactive angiotensin I into active angiotensin II
DNAJC5 611203 CLN4B 162350 AD Calcium-dependent neurotransmitter release at nerve endings
DNM1 602377 EIEE31 616346 AD Vesicle trafficking and receptor-mediated endocytosis
DYRK1A 600855 MRD7 614104 AD Regulation of cell proliferation. Brain development
EHMT1 607001 KLEFS1 610253 AD G0/G1 cell cycle transition
FOXG1 164874 RTT 613454 AD Establishment of regional subdivision of the developing brain and telencephalon development
GABRA1 137160 EIEE19 615744 AD Formation of functional GABAergic synapses, mediation of synaptic inhibition
GABRB3 137192 EIEE43 617113 AD Formation of functional GABAergic synapses, mediation of synaptic inhibition
GRIN1 138249 NDHMSD/R 614254 AD, AR Plasticity of synapses that underlies memory and learning
GRIN2A 138253 FESD 245570 AD Higher sensitivity of glutamate and faster NMDA channel kinetics
GRIN2B 138252 EIEE27 616139 AD Brain development, circuit formation, synaptic plasticity, cell migration and differentiation
HNRNPU 602869 EIEE54 617391 AD Formation of ribonucleoprotein complexes in the nucleus with heterogeneous nuclear RNA
KANSL1 612452 KDVS 610443 AD Acetylation of nucleosomal histone H4 on lysine residues involved in transcription regulation
KCNMA1 600150 PNKD3, CADEDS 609446, 617643 AD, AR Control of excitability for the regulation of smooth muscle contraction, tuning of cochlear hair cells, regulation of transmitter release, innate immunity
KCNA1 176260 EA1 160120 AD Regulation of neuron excitability in the hippocampus, downstream effector for G protein-coupled receptors, inhibition of GABAergic inputs to basolateral amygdala neurons, regulation of neurotransmitter release, generation of action potentials and prevention of hyperexcitability in myelinated axons of the vagus nerve
KCNQ2 602235 EIEE7, BFNS1 613720, 121200 AD Regulation of neuron excitability
KCNQ3 602232 BFNS2 121201 AD Regulation of neuron excitability
LGI1 604619 ETL1 600512 AD Regulation of voltage-gated potassium channel activity, neuron growth regulation, cell survival
MBD5 611472 MRD1 156200 AD Heterochromatin binding
MEF2C 600662 MRD20 613443 AD Role in hippocampal-dependent learning and memory through regulation of basal and evoked synaptic transmission. Normal neuron development and distribution, neocortical electrical activity
PRRT2 614386 ICCA, EKD1, BFIS2 602066, 128200, 605751 AD Synaptic transmission in the central nervous system Neurotransmitter release in presynaptic terminals of hippocampal neurons
SCN1A 182389 GEFSP2, EIEE6 604403, 607208 AD Regulation of neurotransmitter release
SCN2A 182390 EIEE11, BFIS3 613721, 607745 AD Regulation of hippocampal replay, important for memory
SCN8A 600702 MYOCL2, EIEE13, BFIS5 618364, 614558, 617080 AD Ion pore region of voltage-gated sodium channel. Essential for rapid membrane depolarization during action potential formation in excitable neurons
SCN9A 603415 GEFSP7 613863 AD Mediation of voltage-dependent sodium ion permeability of excitable membranes
SLC2A1 138140 GLUT1DS1/2 606777, 612126 AD, AR Expressed at the blood-brain barrier, facilitation of glucose transport into the brain
SLC6A1 137165 MAE 616421 AD GABA reuptake into presynaptic terminals
SPTAN1 182810 EIEE5 613477 AD Ca2+-dependent interaction with calmodulin, Ca2+-dependent movement of the cytoskeleton at plasma membrane
STXBP1 602926 EIEE4 612164 AD Release of neurotransmitters via regulation of syntaxin
SYNGAP1 603384 MRD5 612621 AD Regulation of synaptic plasticity and neuron homeostasis
TCF4 602272 PTHS 610954 AD Initiation of neuron differentiation
TSC1 605284 FCORD2 607341 AD (somatic) Negative regulation of anabolic cell growth
TSC2 191092 Tumor suppressor
MTOR 601231 Central regulator of cell metabolism, growth and survival in response to hormones, growth factors, nutrients, energy and stress signals
ZEB2 605802 MOWS 235730 AD Transcriptional inhibitor. Represses transcription of E-cadherin
UBE3A 601623 AS 105830 AD Regulator of synaptic development
ABAT 137150 GABA-transaminase deficiency 613163 AR Catabolism of gamma-aminobutyric acid
ADSL 608222 ADSLD 103050 AR De novo AMP synthesis
ALDH7A1 107323 EPD 266100 AR Catabolism of betaine aldehyde, lipid peroxidation-derived aldehydes, lysine
ASAH1 613468 SMAPME 159950 AR Catabolism of ceramide into sphingosine and free fatty acids
BRAT1 614506 NEDCAS, RMFSL 618056, 614498 AR Regulation of mitochondrial function and cell proliferation
CLN3 607042 CLN3 204200 AR Microtubule-dependent, anterograde transport of late endosomes and lysosomes
CLN5 608102 CLN5 256731 AR Retrograde trafficking of lysosomal sorting
CLN6 606725 CLN4A, CLN6 601780, 204300 AR Degradation of post-translationally modified proteins in lysosomes
CLN8 607837 CLN8, neuronal ceroid lipofuscinosis 8 Northern epilepsy variant 600143, 610003 AR Cell proliferation during neuronal differentiation and protection against cell death
CNTNAP2 604569 PTHSL1 610042 AR Radial and longitudinal organization of myelinated axons. Formation of functionally distinct domains critical for saltatory conduction of nerve impulses in myelinated nerve fibers. Demarcation of the juxtaparanodal region of the axo-glial junction
CSTB 601145 Myoclonic epilepsy of Unverricht and Lundborg 254800 AR Protection against proteases leaking from lysosomes
CTSD 116840 CLN10 610127 AR Protein turnover, and proteolytic activation of hormones and growth factors
EPM2A 607566 Myoclonic epilepsy of Lafora 254780 AR Prevention of formation of glycogen-insoluble aggregates
FOLR1 136430 Neurodegeneration due to cerebral folate transport deficiency 613068 AR Required for normal embryo development and normal cell proliferation
GAMT 601240 CCDS2 612736 AR Important in nervous system development
GATM 602360 CCDS3 612718 AR Embryo and central nervous system development
GOSR2 604027 EPM6 614018 AR Transport of proteins from the cis/medial-Golgi to the trans-Golgi network
IER3IP1 609382 MEDS 614231 AR Regulation of apoptosis. Involved in protein transport between endoplasmic reticulum and Golgi apparatus
KCNJ10 602208 SESAMES 612780 AR Responsible for potassium buffering action of glial cells in the brain
KCTD7 611725 EPM3 611726 AR Control of excitability of cortical neurons
MFSD8 611124 CLN7 610951 AR Transport of small solutes via chemiosmotic ion gradients
NHLRC1 608072 Myoclonic epilepsy of Lafora 254780 AR Misfolded protein degradation via the ubiquitin-proteasome system
PIGN 606097 MCAHS1 614080 AR Glycosylphosphatidylinositol-anchor biosynthesis
PIGO 614730 HPMRS2 614749 AR Glycosylphosphatidylinositol-anchor biosynthesis
PLCB1 607120 EIEE12 613722 AR Synthesis of inositol 1,4,5-trisphosphate and diacylglycerol from phosphatidylinositol 4,5-bisphosphate
PNPO 603287 PNPOD 610090 AR Catalysis of the terminal rate-limiting step of vitamin B6 synthesis
POLG 174763 MTDPS4A/4B, SANDO 203700, 613662, 607459 AR Replication of mitochondrial DNA
PPT1 600722 CLN1 256730 AR Catabolism of lipid-modified proteins during lysosomal degradation
PRICKLE1 608500 EPM1B 612437 AR Involved in the planar cell polarity pathway that controls convergent extension during gastrulation and neural tube closure
PNKP 605610 MCSZ 613402 AR Repair of DNA damage
SCARB2 602257 EPM4 254900 AR Membrane transport and reorganization of the endosomal/lysosomal compartment
SLC19A3 606152 THMD2 607483 AR High affinity thiamine uptake
SLC25A22 609302 EIEE3 609304 AR Transport of glutamate across the inner mitochondrial membrane
STRADA 608626 PMSE 611087 AR G1 cell cycle arrest
TBC1D24 613577 DOORS, EPRPDC, EIEE16, FIME 220500, 608105, 615338, 605021 AR Neuronal projection development
TPP1 607998 CLN2 204500 AR Non-specific lysosomal peptidase which generates tripeptides from lysosomal proteinase breakdown products
WWOX 605131 EIEE28 616211 AR Tumor suppressor gene
ALG13 300776 EIEE36 300884 XLD Protein N-glycosylation
ARHGEF9 300429 EIEE8 300607 XLR Receptor recruitment in GABAergic and glycinergic synapses
ARX 300382 EIEE1 308350 XLR Maintenance of neuron subtypes in the cerebral cortex, axonal guidance in the floor plate
ATP6AP2 300556 MRXSH 300423 XLR Control of V-ATPase pump assembly and acidification of lysosomes. Role in synapse morphology, synaptic transmission
CASK 300172 MICPCH 300749 XLD Regulation of mitochondrial function and cell proliferation
CDKL5 300203 EIEE2 300672 XLR Ciliogenesis
FLNA 300017 PVNH1 300049 XLD Neuroblast migration from ventricular zone into cortical plate. Ciliogenesis. Cell-cell contacts and adherens junctions during brain development. Required for growth cone collapse during axon guidance
IQSEC2 300522 MRX1 309530 XLD Component of postsynaptic density at excitatory synapses. Critical role in cytoskeletal and synapse organization
MECP2 300005 RTT 312750 XLD Essential for embryo development
PCDH19 300460 EIEE9 300086 XL, female restricted Ca2+-dependent cell-adhesion protein primarily expressed in the brain
PIGA 311770 MCAHS2 300868 XLR Necessary for synthesis of N-acetylglucosaminyl-phosphatidylinositol, early intermediate in GPI-anchor biosynthesis
SLC6A8 300036 CCDS1 300352 XLR Required for uptake of creatine by muscles and brain
SLC9A6 300231 MRXSCH 300243 XLD Exchange of protons for Na+ and K+ across endosome membranes. Ca2+ homeostasis
SMC1A 300040 EIEE85 301044 XLD Part of functional kinetochores
SRPX2 300642 RESDX 300643 XLR Promotion of synapse formation
WDR45 300526 NBIA5 300894 XLD Autophagosome assembly

Pathogenic variants may be missense, nonsense, splice-site and small intragenic deletions/insertions. The test guidelines can be found in “Genetics Home Reference” (ghr.nlm.nih.gov). The test is useful for confirming diagnosis, differential diagnosis and recurrence risk evaluation.

The search for pathogenic variants in the genes listed in Table 1 is based on analysis of a multi-gene panel by next generation sequencing of the coding regions and their intron-exon junctions. The test has an analytic sensitivity of 96-100% and an analytic specificity of ≥99%, compared with a diagnostic sensitivity of ≥37% deduced from the literature (8,9). Since epilepsy has high genetic heterogeneity (10), the use in diagnostics of a large panel of genes may speed up the determination of the molecular etiology and/or establish a risk of recurrence in family members for the purpose of planning appropriate preventive and/or therapeutic measures.

Conflict of interest:

Each author declares that he or she has no commercial associations (e.g. consultancies, stock ownership, equity interest, patent/licensing arrangement etc.) that might pose a conflict of interest in connection with the submitted article

References

  • 1.Berg AT, Berkovic SF, Brodie MJ, et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE Commission on classification and terminology, 2005-2009. Epilepsia. 2010;51:676–85. doi: 10.1111/j.1528-1167.2010.02522.x. [DOI] [PubMed] [Google Scholar]
  • 2.Pellock JM. The challenge of neuropsychiatric issues in pediatric epilepsy. J Child Neurol. 2004;19:S1–5. doi: 10.1177/088307380401900101. [DOI] [PubMed] [Google Scholar]
  • 3.Diagnosis and management of epilepsy in adults. A national clinical guideline. 2015 Available at: https://www.guidelinecentral.com/share/summary/56a775bf791d0#section-society . [Google Scholar]
  • 4.Thurman DJ, Beghi E, Begley CE, et al. Standards for epidemiologic studies and surveillance of epilepsy. Epilepsia. 2011;52:2–26. doi: 10.1111/j.1528-1167.2011.03121.x. [DOI] [PubMed] [Google Scholar]
  • 5.National Clinical Guideline Centre (UK) The epilepsies: the diagnosis and management of the epilepsies in adults and children in primary and secondary care. London: Royal College of Physicians (UK) 2012 [Google Scholar]
  • 6.Walls R, Hockberger R, Gausche-Hill M. Philadelphia: Mosby/Elsevier; 2010. Rosen’s emergency medicine: concepts and clinical practice. [Google Scholar]
  • 7.Pong AW, Pal DK, Chung WK. Developments in molecular genetic diagnostics: an update for the pediatric epilepsy specialist. Pediatr Neurol. 2011;44:317–27. doi: 10.1016/j.pediatrneurol.2011.01.017. [DOI] [PubMed] [Google Scholar]
  • 8.Wang J, Gotway G, Pascual JM, Park JY. Diagnostic yield of clinical next-generation sequencing panels for epilepsy. JAMA Neurol. 2014;71:650–1. doi: 10.1001/jamaneurol.2014.405. [DOI] [PubMed] [Google Scholar]
  • 9.Della Mina E, Ciccone R, Brustia F, et al. Improving molecular diagnosis in epilepsy by a dedicated high-throughput sequencing platform. Eur J Hum Genet. 2015;23:354–62. doi: 10.1038/ejhg.2014.92. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. https://www.lice.it/pdf/Percorso_diagnostico_Epilessie_Genetiche_web.pdf . [Google Scholar]

Articles from Acta Bio Medica : Atenei Parmensis are provided here courtesy of Mattioli 1885

RESOURCES